Analysis of Renal and Cardiac Outcomes in Male Participants in the Fabry Outcome Survey Starting Agalsidase Alfa Enzyme Replacement Therapy Before and After 18 Years of Age
Rossella Parini,1,2 Guillem Pintos-Morell,3 Julia B Hennermann,4 Ting-Rong Hsu,5 Nesrin Karabul,6 Vasiliki Kalampoki,7 Andrey Gurevich,7 Uma Ramaswami8 On behalf of the FOS Study Group1Rare Metabolic Diseases Unit, MBBM Foundation, San Gerardo Hospital, Reference Centre for Hereditary Metabolic Diso...
Main Authors: | Parini R, Pintos-Morell G, Hennermann JB, Hsu TR, Karabul N, Kalampoki V, Gurevich A, Ramaswami U |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2020-06-01
|
Series: | Drug Design, Development and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/analysis-of-renal-and-cardiac-outcomes-in-male-participants-in-the-fab-peer-reviewed-article-DDDT |
Similar Items
-
Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis
by: Michael Beck, et al.
Published: (2015-06-01) -
Cardio- Renal Outcomes With Long- Term Agalsidase Alfa Enzyme Replacement Therapy: A 10- Year Fabry Outcome Survey (FOS) Analysis
by: Ramaswami U, et al.
Published: (2019-10-01) -
Long-term outcomes with agalsidase alfa enzyme replacement therapy: Analysis using deconstructed composite events
by: Michael Beck, et al.
Published: (2018-03-01) -
Updated Evaluation of Agalsidase Alfa Enzyme Replacement Therapy for Patients with Fabry Disease: Insights from Real-World Data
by: Feriozzi S, et al.
Published: (2024-04-01) -
New insights in efficacy of different ERT dosages in Fabry disease: Switch and switch-back studies data following agalsidase beta shortage. Update of systematic review
by: Eleonora Riccio, et al.
Published: (2023-01-01)